Biovica Unlocks US Market: A New Dawn for Cancer Care

Biovica International, a pioneering force in blood-based cancer monitoring, has made a significant stride with the acquisition of an out-of-state permit for New York State. This regulatory milestone opens the entire US market for Biovica, allowing its flagship product, DiviTum® TKa, to reach patients and healthcare providers across the nation. This move is set to revolutionize cancer care, providing a new tool for oncologists to monitor cancer progression and therapy effectiveness.

The New York State permit grants access to over 20 million potential patients, the fourth most populous state in the country. This expansion not only consolidates Biovica's position as a leading player in its field but also validates the high degree of quality and compliance of its lab with regulatory requirements. With this approval, Biovica's DiviTum® TKa can now be offered through its lab in San Diego, further enhancing the company's operational efficiency.

Biovica's CEO, Anders Rylander, expressed his enthusiasm about the permit, emphasizing the new opportunities it presents in this important market. New York State houses numerous leading medical centers, and the permit opens doors to potential patients and partnerships. Rylander is proud that patients and their doctors across the entire US can now utilize DiviTum's help in their breast cancer treatment.

Biovica's DiviTum® TKa measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insights into therapy effectiveness in several clinical trials, with its first application focused on treatment monitoring of patients with metastatic breast cancer. Biovica's vision, "Improved care for cancer patients," is set to become a reality as the company continues to collaborate with world-leading cancer institutes and pharmaceutical companies.



The New York State permit is a testament to Biovica's commitment to regulatory compliance and high-quality lab standards. As Biovica continues to grow its US presence, we can expect an increased focus on strategic partnerships that leverage the company's strengthened market position. The revenue generated from the expanded US market can fuel global product development and innovation, allowing Biovica to invest in R&D and expand its assay portfolio.

In conclusion, Biovica's New York State permit is a game-changer, opening the entire US market and solidifying the company's position as a leader in blood-based cancer monitoring. As Biovica continues to grow and innovate, it is poised to make a significant impact on cancer care, improving the lives of patients and healthcare providers alike.